Ann: Appendix 4E and Annual Report, page-37

Potential annual revenue for each if they succeed

Azer-cel: Targeting relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Estimated peak annual revenue potential is around $500 million, assuming market penetration and pricing.

OnCARlytics (CF33-CD19): Targeting a broader market with oncolytic virus therapy combined with CAR T. Estimated peak annual revenue potential could be around $300 million, given the innovative approach.

PD1-Vaxx: Targeting PD-1 pathway similar to other immunotherapies. Estimated peak annual revenue potential might be around $200 million.

HER-Vaxx: Targeting HER2-positive gastric cancer. Estimated peak annual revenue potential could be $150 million.

Partnership , patents collaborating with other therapies is not calculated, there is something called cumulative POS for calculating the current pricing when biotech's are still not producing, I have data for Azar-cel, currently funds and brokers are calculating a cumulative POS of 62 mil hypothetically for Azar-cell alone.

somebody asked why big funds are still not interested and why Imugene keeps presenting in various broker road shows, this is because the dumb shits in broker house have softwares where they have all sorts of models and they do mathematical modelling ( I have the number by those models but will not divulge here as I dont want gullibles here to just jump in FOMO and get burnt) but lets keep the 0.4 ish which the analysts modelled is very very very close(if all goes well), Imugene wants them to put additional data in their modelling called "variables" and see how they rate them, many factors are fed in as variables
Market conditions

Investor sentimentThe strength of other pipeline productsPartnerships and funding strategies
and also read my previous blurb and read this, this will make a lot of sense